On the stock market since 2003, it operates in the world of health and science. It has 18,000 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
There is $8.3B in the vault; even if every debt were paid off, $4.3B would remain.
Over the last 12 months, company executives reported 46 buys and 12 sells. Management buying with its own money is usually read as a good sign.
The stock trades 15% above the average analyst price target.
The growth engine is running at low revs right now. Report-card grade: 30/100.
Costs swallow the gains that sales growth brings in.
On our five-subject report card, MOH sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: MOH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.